CELZ

Creative Med Technology Hldgs

• Benzinga·05/08 22:12

  Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate

• PUBT·05/08 20:46

  Creative Medical net loss narrows 14.31% to $1.4 million in Q1 FY26

• TipRanks·04/28 15:53

  Creative Medical knee data ‘highly positive,’ says Roth Capital

• TipRanks·04/28 13:57

  Creative Medical reports pilot study of Ultrasome meets priamry endpoint

• PUBT·04/28 13:10

  Creative Medical says Ultrasome knee osteoarthritis pilot study hits 93% response rate

• Benzinga·04/28 13:04

  Creative Medical Technology Announces Results From Pilot Study Of Ultrasome, Proprietary Cell-Free Regenerative Therapy For Treatment Of Osteoarthritis Of Knee

• Reuters·04/28 13:01

  CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. REPORTS BREAKTHROUGH 93% RESPONSE RATE IN ULTRASOME™ KNEE OSTEOARTHRITIS PROGRAM, EXPANDING CELZ-201 PLATFORM INTO SCALABLE CELL-FREE REGENERATIVE THERAPIES

• Reuters·03/20 20:46

  Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000

• Reuters·02/10 14:14

  CREATIVE MEDICAL TECHNOLOGY HOLDINGS ACHIEVES SECOND WHO INN MILESTONE, STRENGTHENING GLOBAL REGULATORY POSITIONING ACROSS EXPANDING CELL THERAPY PIPELINE

• TipRanks·02/10 14:06

  Creative Medical achieves second WHO INN milestone

• Reuters·02/10 14:00

  Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline

• Benzinga·01/20 12:05

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• NASDAQ·01/13 15:50

  Creative Medical's ADAPT Trial In Chronic Lower Back Pain Shows Functional And Pain Improvements

• TipRanks·01/13 14:25

  Creative Medical announces interim data from ADAPT trial of CELZ-201

• Benzinga·01/13 14:17

  Creative Medical Announces Interim 180-Day Follow-Up Data From FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201, Proprietary Perinatal Tissue-Derived Cell Therapy For Chronic Lower Back Pain